Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
April 03, 2024 08:00 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
navy-cuv-logo-rgb-1200x628px.png
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
March 28, 2024 04:25 ET | Clinuvel Pharmaceuticals Limited
Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing in Dusseldorf, Germany.
Logo 1.png
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
March 27, 2024 08:05 ET | Aeterna Zentaris Inc
- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into...
Logo.png
Nutra Pharma Corp. Reaches Settlement with SEC
March 22, 2024 16:39 ET | Nutra Pharma Corp.
Nutra Pharma Corp. Reaches Settlement with SEC
SERB Pharmaceuticals
SERB Pharmaceuticals grants exclusive license to M8 Pharmaceuticals, an Acino company, to bring Voraxaze® (Glucarpidase) to cancer patients in Latin America
March 20, 2024 10:00 ET | SERB Pharmaceuticals
Paris, March 20, 2024 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company, and M8 Pharmaceuticals, an Acino company (“M8”) are collaborating to bring an...
logo 600X600.png
Feeding Tubes Market Size to Surpass Around US$ 9.69 Billion 2030, Recording a CAGR of 6.2% | Report by CoherentMI
March 20, 2024 06:21 ET | CMI
Burlingame, March 20, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, Feeding Tubes Market was valued at US$ 6.34 Billion in the year 2023 and is anticipated to reach US$ 9.69...
US Retinal Specialis
US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies
March 19, 2024 14:20 ET | Spherix Global Insights
EXTON, PA, March 19, 2024 (GLOBE NEWSWIRE) -- Gene therapies have emerged as a ray of hope, particularly in the realm of eye diseases. The focus on the eye has provided researchers with a promising...
PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval
PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval
March 18, 2024 14:37 ET | PRISM MarketView
PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval
FDA’s Approval of Br
FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
March 14, 2024 17:18 ET | Global Liver Institute
Washington, DC, March 14, 2024 (GLOBE NEWSWIRE) -- Today, Global Liver Institute (GLI) recognizes the importance of the first approval by the U.S. Food and Drug Administration (FDA) of a medication...
IgA Nephropathy Pipe
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
March 14, 2024 15:11 ET | Spherix Global Insights
EXTON, PA, March 14, 2024 (GLOBE NEWSWIRE) -- The past several years have brought a transformative shift to the IgA nephropathy (IgAN) treatment landscape, including the introduction of two new...